As the existing comprehensive recommendations for cancer control policies are mostly derived from Western countries, non-Western nations should strive to tailor their own policies based on their local lifestyle, burden of cancer and characteristics of the local healthcare system.
Newer molecular tests for high-risk human papillomavirus (hrHPV) may provide a cost-effective means for cervical cancer screening for low-to-middle income countries (LMICs), with results comparable to cervical biopsies.
The Union for International Cancer Control (UICC) invites cities in Asian countries to participate in the global initiative of City Cancer Challenge (CCC) and upgrade their healthcare services for cancer patients.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Oncology - Malaysia digital copy today!
An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.
Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
Drawing from experience as a key investigator in landmark
clinical trials (including PALOMA, MONALEESA and
MONARCH), and his clinical experience with
CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his
insights into the current evidence of using CDK4/6 inhibitors
to treat HR+/HER2- ABC.